Diagnosing Diagnostics II: Tools vs. Teaching - Ep 10
Send us a text What would create greater value for patients and providers? Professor Mary Rinella of Northwestern University and Suneil Hosmane of GenFit join Stephen, Louise, and Roger to explore which of these strategies can do the most to improve patient diagnosis and management. The answer might surprise you.
18 Juni 20201h 3min
International NASH Day is Here! - Ep 9
Send us a text Surfing the NASH Tsunami celebrates a growing and increasingly important global event for the Fatty Liver community. Global Liver Institute President & CEO Donna Cryer joins the Surfers to discuss the focus, passion and advocacy that have shaped and grown International NASH Day. Learn how IND started and what it represents today. As you listen, envision the role you can play in the future of Fatty Liver advocacy and education.
11 Juni 202054min
Diagnosing Diagnostics – Part I - Ep 8
Send us a text Room for improvement GenFit Head of Global Diagnostics Suneil Hosmane joins the Surfers in exploring the current strengths and drawbacks of Fatty Liver diagnostics. The conversation considers the needs of drug developers, clinicians and patients, and highlights opportunities for improving diagnostic options.
4 Juni 202050min
NASH-Ville - Part 2: Better Days Ahead? - Ep 7
Send us a text Reviewing press releases reporting preliminary findings from six recently announced Phase 2 trials Stephen Harrison leads the Surfers, with guest Louise Campbell, through an examination of six Phase 2 clinical trials that put forth press releases during the last three months. In all, the discussion created an air of optimism based on better clinical outcomes than we have seen with earlier NASH drugs, all from medicines with distinct but potentially complementary modes of action.
28 Maj 20201h 1min
What’s in a Name: NAFLD or MAFLD? - Ep 6
Send us a text Exploring the controversy over the name(s) to use when describing Fatty Liver disease(s) Professor Quentin Anstee joins the Surfers for a thoughtful consideration of the factors that should drive the decision on what name(s) to use for different Fatty Liver diseases. The group considers a range of issues from our level of scientific knowledge to the semiotics of naming to how patients react to certain disease descriptions, all in a stimulating, freewheeling discussion.
21 Maj 202052min
Wild Times In NASH-Ville – Part I - Ep 5
Send us a text Clinical trial results that are changing how we look at NASH Stephen Harrison leads a review of two recent Phase 3 data statements: the outcome of GenFit’s RESOLVE-IT trial and Madrigal Pharmaceuticals’ recent press release on the extension of its MAESTRO Phase 3 NASH trial. Listen to a thoughtful, far-reaching sometimes funny conversation as the group explores WILD TIMES IN NASH-VILLE – PART I.
15 Maj 20201h 3min
When You Get To A Fork In The Road - Ep 4
Send us a text Three possible scenarios for development of the NASH market. Roger Green presents three possible directions for the NASH market over the next 5-10 years and asks our panelists, including our guest, renowned nurse and patient advocate Louise Campbell, to suggest critical market-driving factors. Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
7 Maj 202059min
C-Suite COVID-19 Challenges - Ep 3
Send us a text Critical considerations for companies developing NASH drugs Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES. Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
30 Apr 202053min
